The Federal Reserve's decision to hold interest rates steady signals a strategic pause, not an end to its easing cycle. We break down the immediate and future impacts on everything from credit cards to the housing market.
Medical device maker ResMed (RMD) reported fourth-quarter revenue of $1.42 billion, an 11% year-over-year increase that surpassed Wall Street forecasts. Non-GAAP earnings per share reached $2.81, also topping analyst expectations.
The floral and gift e-commerce giant 1-800-FLOWERS reported a 9.5% year-over-year revenue decline to $702.2 million for its fiscal fourth quarter, aligning with Wall Street's subdued expectations. However, disciplined cost management fueled a significant earnings beat, with non-GAAP EPS of $1.20 surging 39.5% above estimates.
Trane Technologies (TT) surpassed Wall Street expectations for Q4 2025, driven by surging demand in commercial HVAC systems and data center infrastructure. The company reported revenue of $5.14B, up 5.5% year-over-year, with earnings per share of $2.86. Management expressed confidence for 2026, citing a record order backlog.
First Citizens BancShares delivered Q4 revenue and adjusted EPS above analyst forecasts, yet its stock fell. While management pointed to strong fundamentals, analysts probed pressures on margins, tech spending, and integration challenges.
The business services sector has outperformed, riding a wave of corporate demand for efficiency. But with economic sensitivity looming, we analyze two companies with robust models and one where caution may be warranted.
While lofty price targets can signal opportunity, a closer look reveals that not all consensus forecasts are created equal. We examine one company poised to deliver and two where investor caution may be warranted.
Applied Optoelectronics (AAOI) is positioning itself at the forefront of the AI infrastructure build-out, securing a significant 800G transceiver order from a hyperscale customer and expanding its Texas manufacturing footprint. While these moves signal strong revenue momentum, they also amplify existing concerns over customer concentration and profitability.
Cullen/Frost Bankers (NYSE: CFR) reported robust fourth-quarter results, beating analyst estimates on earnings and revenue. The Texas-based regional bank also announced a new $300 million share repurchase program and raised its guidance, fueling a debate on whether its current valuation fully reflects its growth trajectory.
Hershey (HSY) shares are drawing renewed attention from Wall Street as upbeat earnings sentiment converges with the launch of its innovative Jolly Rancher Heat Wave Gummies. While recent momentum is strong, valuation metrics present a complex picture for the iconic confectioner.
Former House Speaker Nancy Pelosi has sold between $1 million and $5 million worth of Disney shares, a move that spotlights the entertainment giant's struggle to navigate declining linear TV revenues and intense streaming competition, even as its parks and direct-to-consumer segments show resilience.
Fresh from its spin-off, GE Vernova is finalizing a deal to acquire transformer maker Prolec GE, a strategic move to bolster its electrification portfolio and capitalize on surging global demand for grid infrastructure and power equipment.
Amid a broader leadership restructuring, financial giant Charles Schwab has appointed its CIO, Dennis Howard, to lead a consolidated unit overseeing technology, operations, and data, signaling a strategic shift to deepen the integration of IT with core business functions.
Analyst firm Clear Street has raised its price target for Critical Metals Corp. (CRML) to $20, citing a strategic joint venture with a Saudi industrial group to build a rare earth processing facility. The move aims to diversify supply chains away from China and support Western defense needs.
Citi has updated its model for GlobalFoundries, lifting the price target to $42 and extending its valuation horizon to 2027. The move follows the chipmaker's strategic acquisition of Synopsys' ARC Processor IP business, aimed at accelerating its physical AI roadmap.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Once a fintech stalwart, Fiserv shares have cratered 70% in a year. As its 'One Fiserv' restructuring plan kicks in, investors are grappling with whether the beaten-down stock is a bargain or a warning sign.
While Roth accounts dominate the retirement planning conversation, a closer look at current tax laws and long-term income strategies reveals a compelling case for prioritizing pre-tax contributions. We examine the data with an expert and explore what gold's historical returns tell us about diversification.
WisdomTree reports record assets under management of $144.5 billion for 2025, driven by $8.5 billion in net inflows and strategic acquisitions. The firm forecasts continued margin expansion and highlights digital assets, European thematics, and private markets as key growth engines for the coming year.
